Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Gene expression after treatment with Nutlin 3a (Nut) and Selinexor (Sel) in Neuroblastoma Cells

ABSTRACT: Gene expression after treatment with Nutlin 3a (Nut) and Selinexor (Sel) in Neuroblastoma Cells

PROVIDER: PRJNA565248 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR10108573.fastq.gz	Fastqsanger.gz
	SRR10108574.fastq.gz	Fastqsanger.gz
	SRR10108575.fastq.gz	Fastqsanger.gz
	SRR10108576.fastq.gz	Fastqsanger.gz
	SRR12979655.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 12

Similar Datasets

Gene expression after treatment with Nutlin 3a (Nut) and Selinexor (Sel) in Neuroblastoma Cells

Project description:Gene expression after treatment with Nutlin 3a (Nut) and Selinexor (Sel) in Neuroblastoma Cells RNA from NBAT1 knockdown and its respective control (Csh) SH-SY5Y cells after nutlin-3a (10 uM) or DMSO treatement were isolated and sequenced using BGI DNBseq. IMR32 cells were treated with either DMSO, Nut, Sel and with both Nul and Sel and RNA was isolated following treatemnet We observed that knowndown of the NBAT1 lncRNA in NB cells leads to perturbation of the P53 mediated gene expression. Combination treatment with with Nul and Sel in IMR32 cells leads to higher P53 mediated gene expression.

2020-12-23 | GSE137366 | GEO

Expression data from human sarcoma patient samples treated with either vehicle control or Nutlin-3a

Project description:This study has examined the molecular mechanisms underlying sensitivity of sarcomas to Nutlin-3a, a non-genotoxic activator of the p53 pathway. Human patient material was collected immediately following surgical resection, dissected into small pieces and ex planted onto gelatin sponges immersed in media containing either vehicle control or Nutlin-3a (10uM and/or 50uM) for 48 hours. Nutlin-3a represents a novel targeted therapy for the treatment of sarcomas. We have examined expression profiles of genes upregulated in sarcoma patient derived tissues following nutlin-3a treatment ex vivo 16 samples ((Vehicle control and Nutlin-3a (10uM and 50uM) treated samples)) from 6 sarcoma patients

2014-03-10 | E-GEOD-48296 | biostudies-arrayexpress

ATAC-seq from Nutlin-3a-treated MCF-7 cells

Project description:ATAC-seq from MCF-7 cells treated with Nutlin-3a or DMSO control

2024-09-18 | GSE250017 | GEO

Expression data from human sarcoma patient samples treated with either vehicle control or Nutlin-3a

2014-03-10 | GSE48296 | GEO

Pharmacological inhibition of WIP1 sensitizes acute myeloid leukemia cells to MDM2 inhibitor Nutlin-3a

Project description:The wild-type p53-inducible protein phosphatase WIP1, encoded by the PPM1D gene, is a negative regulator of p53 and is involved in cell cycle control and DNA damage stress-response. In acute myeloid leukemia (AML), the restoration of p53 activity through MDM2 inhibition proved efficacy in a number of combination strategies. We investigated the therapeutic potential of its inhibition through the selective WIP1 inhibitor (WIP1i) GSK2830371, in association with the MDM2 inhibitor Nutlin-3a (Nut-3a) in a panel of AML cell lines and performed gene expression analysis of single agent and combined treatments. A p53-related signature was significantly upregulated in the TP53-wildtype MV-4-11 AML cell line. Moreover, drug-specific transcriptional changes likely contribute to the synergistic combination effect.

2021-05-06 | GSE156182 | GEO

Transcriptomics analysis in 3T3L1 preadipocytes with activation of p53 via Nutlin-3a treatment

Project description:3T3L1 preadipocytes were treated with DMSO control and Nutlin-3a (prepared in DMSO) and total RNA extracted from the treated cells were subjected to illumina based RNA-seq to analyze and compare transcriptome to understand gene expression regulation influenced by p53 activation via Nutlin-3a treatment.

2018-07-05 | GSE100811 | GEO

Nutlin-3a induced changes in the transcriptome of MCF-7 cells

Project description:RNA-seq from MCF-7 cells treated with Nutlin-3a or DMSO control

2024-09-18 | GSE216721 | GEO

Nanopore long-read sequencing from Nutlin-3a-treated MCF-7 cells

Project description:Nanopore long-read sequencing from MCF-7 cells treated with Nutlin-3a or DMSO control

2024-09-18 | GSE226080 | GEO

QuantSeq from Nutlin-3a-treated MCF-7, U2OS, and RPE-1 cells

Project description:QuantSeq from MCF-7, U2OS, and RPE-1 cells treated with Nutlin-3a or DMSO control

2024-09-18 | GSE223513 | GEO

mRNA-seq from Nutlin-3a, doxorubicin, and DMSO treated HCT116 p21-/- cells

Project description:We sequenced mRNA from HCT116 p21-/- cells treated with Nutlin-3a, doxorubicin, or DMSO for 24 h.